ReviewApplied microbiology and biotechnology2026
Application of clearance strategies for extractables and leachables and advances in process modeling.
Review in Applied microbiology and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Single-use devices made from plastic materials and used in the manufacturing of pharmaceutical products were identified as sources of extractables and potentially process equipment-related leachables (PERLs), which may interfere with process performance and product quality. In this contribution, the sinks of PERLs in biopharmaceutical processes are explored and the underlying physical-chemical mechanisms are discussed. This includes an overview of studies on leachable clearance with ultrafiltration/diafiltration operations (UF/DF) and chromatographic steps, filter rinsing, and adsorption. Literature reveals that dilution and phase separation are the main drivers for reducing PERL exposure along a process. Integrating extractables release and established physical processes of dynamic dilution and phase separation allows to set up and populate mathematical models which can predict the fate of PERLs in batch and continuous bioprocessing. Integrating the fate of PERLs improves process understanding, supports process qualification studies, and, ultimately, strengthens the patient safety assessment. KEY POINTS: • It is possible to demonstrate that biopharmaceutical processes can significantly reduce PERLs. • Various process operation steps are identified as sinks for PERLs, and the fate of PERLs is predictable with simple mathematical models. • Using PERL exposure models improves process understanding and enhances the safety assessments for single-use devices used in bioprocessing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.